AIM
PTX

Acrospire Investment Management’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

Acrospire Investment Management’s Portfolio PTX Stock Details PTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-11,026
Closed -$21K – 2714
2016
Q4 		$21K Buy
+11,026
New +$39.9K 0.01% 1756

Other funds holding PTX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 19.31% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Acrospire Investment Management's PTX Position: Q1 2017 in Review

Acrospire Investment Management sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q1 2017, closing a stake of 11,026 shares — an estimated $21K sold.

Acrospire Investment Management first reported a position in PTX in Q4 2016 and held it in 1 quarter. The position peaked at $21K in Q4 2016. 31 funds tracked by Wall St. Rank hold PTX as of Q1 2017.

  • Acrospire Investment Management reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q1 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 11,026 Pernix Therapeutics Holdings, Inc. shares in Q1 2017, an estimated $21K.
  • Acrospire Investment Management first reported a position in Pernix Therapeutics Holdings, Inc. in Q4 2016 and held it in 1 quarter.
  • Acrospire Investment Management's Pernix Therapeutics Holdings, Inc. position peaked at $21K in Q4 2016.
  • 31 funds tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q1 2017.

Based on Acrospire Investment Management's 13F filing for Q1 2017, filed 4 May 2017.